Abstract
Since the year 2000, Danish rheumatologists have been collecting data on a routine basis in the nationwide DANBIO registry, which includes all rheumatologic patients receiving biological drugs. Demographic data, markers of disease activity, current treatment, serious and non-serious adverse events and reasons for discontinuation are registered at each visit either on paper forms or on-line. By June 2005, approximately 3000 treatment courses (18,000 visits) were in the registry, corresponding to close to 90% of eligible patients. Rheumatoid arthritis was the most prevalent diagnosis (75%) followed by ankylosing spondylitis (11%) and psoriatic arthritis (7%). Infections occurred in 43% of the treatment series.
Bidragets oversatte titel | DANBIO: a nationwide registry of biological therapies in Denmark |
---|---|
Originalsprog | Engelsk |
Tidsskrift | Clinical and Experimental Rheumatology |
Vol/bind | 23 |
Udgave nummer | 5 Suppl 39 |
Sider (fra-til) | S205-7 |
ISSN | 0392-856X |
Status | Udgivet - 2005 |